Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827271 | 0.82 | NPY5R (0.50) | DHFRSLC2A1NPY5RKDM4EMAPT | |
| SCHEMBL6827021 | 0.81 | DHFR (0.39) | DHFRSLC2A1NPY5RHTR2AHTR2C | |
| SCHEMBL6826791 | 0.79 | CYP1A2 (0.40) | DHFRSLC2A1NPY5RPIK3R1PIK3CA | |
| SCHEMBL1150214 | 0.78 | MAPT (0.40) | KDM4EPIK3R1PIK3CAMAPT | |
| SCHEMBL14752432 | 0.72 | DNM1 (0.44) | DHFRSLC2A1NPY5RHTR2AHTR2C | |
| SCHEMBL27586377 | 0.69 | DHFR (0.33) | DHFRSLC2A1NPY5R | |
| Hydrochloric Acid SCHEMBL6828981 | 0.68 | NPY5R (0.40) | DHFRSLC2A1NPY5RMAPT | |
| SCHEMBL6826761 | 0.65 | DHFR (0.43) | DHFRSLC2A1NPY5RHTR2AHTR2C | |
| SCHEMBL23223692 | 0.63 | KIT (0.52) | KDM4EMAPT | |
| SCHEMBL20957528 | 0.62 | DNM1 (0.49) | HTR2AHTR2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1531527-A | Carbazole derivatives and their use as neuropeptide Y5 receptor ligands | — | 2004-09-22 | — | — | CN | disclosed |
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | DHFR 3790/4885SLC2A1 4007/4885NPY5R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.